Health
Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward – TCTMD
DREAM-HF provides hints of an anti-inflammatory effect and benefits beyond the heart, setting up future trials.
Targeted injection of mesenchymal precursor cells (MPCs) into the myocardium is safe but does not reduce recurrent nonfatal decompensated heart failure (HF) events in patients with chronic HF with reduced ejection fraction (HFrEF), the randomized DREAM-HF…
Continue Reading
-
Business17 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
General16 hours agoPatients speak out after Brisbane doctor accused of ‘excessive’ pap smears, kissing woman on lips
-
Business16 hours agoHere’s what analysts expect for the BHP share price in the coming year
-
Business19 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM